DrugInformations.org

The following statement was issued today by the Biotechnology Industry Organization (BIO) regarding a new survey from the AARP on price trends for biotechnology drugs: “The report issued yesterday by the AARP on price trends for specialty drugs ignores the many factors that counter and mitigate the price trends mentioned in this analysis. The report focuses on data that is only a proxy for drug pricing in Medicare’s Part D program.

More: continued here

No Comments »

Following a very successful first event in 2007, the Drug Information Association’s (DIA’s) 2nd Annual Clinical Forum: Data Driven Drug Development Decisions (October 20-23, 2008; Ljubljana, Slovenia) will focus on clinical data.

More: continued here

No Comments »

Two newspapers recently published editorials addressing Eli Lilly and Merck’s announcements last week that they will publicly disclose some fees paid to physicians beginning next year. Summaries of the editorials appear below.

More: continued here

No Comments »

New drugs that receive fast track designation by the U.S. Food and Drug Administration (FDA) experience shorter clinical and approval times compared to drugs without the designation, according to a recently completed study of the first decade of the fast track program conducted by the Tufts Center for the Study of Drug Development. Total average clinical and approval time for fast track drugs was 5% faster than for all drugs — 73.1 vs. 77.

More: continued here

No Comments »

UCLA scientists have succeeded in making unique nanoscale droplets that are much smaller than a human cell and can potentially be used to deliver pharmaceuticals. “What we found that was unexpected was within each oil droplet there was also a water droplet - a double emulsion,” said Timothy Deming, professor and chair of the UCLA Department of Bioengineering and a member of both the California NanoSystems Institute (CNSI) at UCLA and UCLA’s Jonsson Cancer Center.

More: continued here

No Comments »

As part of its commitment to providing its customers with comprehensive services that span the entire clinical supply chain, Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial supplies and services, has enhanced its global Phase III capabilities.  Its latest Phase III investments include the upgrade of its Kalish large-scale bottling line at its U.S.

More: continued here

No Comments »

This Analysis Showed That Multaq(R) (Dronedarone) Decreased the Risk of Stroke by 34% in Patients With Atrial Fibrillation or Atrial Flutter Already Adequately Treated by Antithrombotic Therapy The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.

More: continued here

No Comments »

Research and Markets has announced the addition of the “Biopharmaceuticals in the US and European Markets” report to their offering.

More: continued here

No Comments »

Forest Laboratories, Inc. (NYSE: FRX) and Laboratorios Almirall, S.A. announced results from two global Phase III studies of aclidinium bromide, a novel long-acting inhaled anticholinergic for the treatment of patients with chronic obstructive pulmonary disease (COPD).

More: continued here

No Comments »

CV Therapeutics, Inc. (Nasdaq: CVTX) announced that the company has enrolled the first patient in a Phase 1 trial of CVT-3619, a novel oral compound for potential treatment of cardiometabolic diseases. The U.S. Food and Drug Administration recently accepted the Company’s investigational new drug application for CVT-3619, a partial A1 adenosine receptor agonist.

More: continued here

No Comments »